Application progress of disease modifying drugs in neuromyelitis optica spectrum disorder
10.11958/20161120
- VernacularTitle:疾病修饰药物在视神经脊髓炎谱系疾病中的应用进展
- Author:
Chao ZHANG
;
Chunyang WANG
;
Bin HAN
;
Chunsheng YANG
;
Li YANG
- Keywords:
neuromyelitis optica;
aquaporin 4;
immunotherapy;
disease modifying drugs;
neuromyelitis optica spectrum disorder;
rituximab;
tocilizumab
- From:
Tianjin Medical Journal
2017;45(1):100-103
- CountryChina
- Language:Chinese
-
Abstract:
Neuromyelitis optica spectrum disorder (NMOSD) is an autoimmune disease of the central nervous system that is characterized by inflammatory demyelinating lesions and axonal degeneration in optic nerve and spinal cord. It has high relapse rate and high disability rate. In recent years, as the studies on mechanisms of NMOSD, related immune therapy strategies have been developed rapidly. These immunologic interventions are collectively called the disease modifying therapy, which are helpful in improving the course and outcome of the disease. In this review, the latest treatment progress in NMOSD is summarized to guide clinical choice and application of the medication.
